You are now leaving www.huliohcp.com, a Biocon Biologics website. The website you are about to access is not owned or controlled by Biocon Biologics Inc.
Biocon Biologics Inc. assumes no responsibility for and makes no warranties or representation of any kind as to the accuracy, currency, or completeness any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Biologics, and a link to this website from another website does not imply a relationship between Biocon Biologics and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party's terms and policies (including its privacy policy). Biocon Biologics shall not be liable for any direct, indirect, consequential, incidental or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.
INDICATIONS
Rheumatoid Arthritis: HULIO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HULIO can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
Juvenile Idiopathic Arthritis: HULIO is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HULIO can be used alone or in combination with methotrexate.
Psoriatic Arthritis: HULIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HULIO can be used alone or in combination with non-biologic DMARDs.
Ankylosing Spondylitis: HULIO is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
Crohn’s Disease: HULIO is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
Ulcerative Colitis: HULIO is indicated for the
treatment of moderately to severely active ulcerative colitis in
adult patients.
Limitations of Use:
The effectiveness of adalimumab products has not been
established in patients who have lost response to or were
intolerant to TNF blockers.
Plaque Psoriasis: HULIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HULIO should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
Hidradenitis Suppurativa: HULIO is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.
Uveitis: HULIO is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
Enroll Your Patient Today
Download the Hulio360™ Enrollment and Prescription Form
Then fax your completed form to 1-866-335-7539.
Download the FormYou can also e-prescribe your HULIO prescription by searching for The Lash Group in your EHR.* Be sure to include your patient’s mobile number.†
*The Lash Group, 1800 Innovation Pt, Fort Mill, SC 29715; NCPDP; 423942.
†By providing the patient's phone number, you represent that your patient is aware of the disclosure and has given consent to be contacted regarding this prescription, and by the fulfillment pharmacy.
EHR=electronic health record.
HULIO Bridge Program
Terms & Conditions
The HULIO Bridge Program (“Bridge Program”) provides Hulio® (adalimumab-fkjp) injection (“HULIO”) at no cost for a one time, one month fill, to eligible, insured patients who have been prescribed HULIO for an indication, and whose initial coverage is delayed, including delay as a result of a prior authorization requirement. Patients must be insured and continue to pursue insurance coverage for HULIO with their healthcare provider. Patients must be residents of the United States or its territories. The Bridge Program is not available to patients who are uninsured or where prohibited by law. Neither prescriber nor patient may submit a claim for reimbursement for all, or any part of the benefit received by the patient through this Bridge Program to any public or private third-party payer or any federal or state health care program. Patient must not count free product dispensed pursuant to this Bridge Program towards any cost obligations, such as Medicare Part D True Costs (TrOOP). No purchase necessary. The Bridge Program is not health insurance, nor is participation a guarantee of insurance coverage. Patients have no obligation to continue use of HULIO. Other limitations may apply. Biocon Biologics reserves the right to rescind, revoke, or amend the Bridge Program at any time without notice.